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Background: Several studies have reported a positive relationship between lung function impair-
ment and the metabolic syndrome. This is most usually explained by abdominal adiposity.
We hypothesized that the main determinant of the association between lung function impair-
ment and abdominal obesity is the presence of visceral fat.
Methods: The present study is a cross-sectional analysis of 98 non-diabeticmen aged between 50
and 70 years with themetabolic syndrome. The amount of visceral and subcutaneous adipose tis-
sue was determined by an MRI scan. The association between visceral fat and measures of lung
function (FEV1, FVC, exhaled and NO) was assessed using linear regression.
Results: 98 participants were included in this analysis. Therewas a linear inverse association be-
tween visceral fat and both FEV1 and FVC. None of the other different fat-relatedmeasurements
(subcutaneous fat, waist circumference and BMI) or features of the metabolic syndrome were
found to be associated with these lung function measurements.
Conclusion: In non-diabetic subjects with the metabolic syndrome and a lung function that is
within the normal range, visceral fat is negatively correlated with FEV1 and FVC.
ª 2013 Elsevier Ltd. All rights reserved.ersity Medical Center, Department of Pulmonology, PO Box 9600, 2300 RC Leiden, The Netherlands.
66927.
, willemienthijs@hotmail.com (W. Thijs).




BMI body mass index
COPD chronic obstructive pulmonary disease
CVD cardiovascular diseases
ERV expiratory reserve volume
FEV1 forced expiratory volume in one second
FVC forced vital capacity
HDL high-density lipoprotein cholesterol
hs-CRP high sensitivity C-reactive protein
MRI Magnetic Resonance Imaging
NO exhaled nitric oxide
TG triglyceride
VC vital capacity
352 W. Thijs et al.Introduction Resonance Imaging (MRI), an imaging technique that allowsObesity is increasing and contributes to the overall burden
of disease worldwide [1]. The prevention of this chronic
disease is one of the priorities of the World Health Orga-
nization [2]. In population studies there is an association
between reduced FEV1 and cardiovascular events [3,4]. In
addition, it is established that obesity is associated with
reduced lung volumes [5].
In obese patients the distribution of fat appears to be an
important contributing factor to morbidity and healthy
survival [6,7]. Especially an increase in visceral fat is
associated with diabetes and the metabolic syndrome [8,9].
Various studies have found an association between type 2
diabetes mellitus and impaired lung function [10e14].
Furthermore, in large population based studies a positive
relationship has been found between lung function
impairment and features of the metabolic syndrome, pre-
dominantly abdominal adiposity [15e17].
Since subcutaneous fat and visceral fat differ in
composition and function, and both contribute to abdom-
inal obesity [18], it is relevant to establish the contribution
of each to the association between abdominal obesity and
lung function. Recently, it has become clear that adipo-
cytes present in visceral fat produce more pro-
inflammatory mediators than adipocytes present in subcu-
taneous fat [19]. In view of the major role of inflammation
in lung function impairment [20], visceral fat could
contribute to decreased lung function in central obesity by
a different mechanism than the mechanical factors that
have been suggested to explain the association between
abdominal obesity and decreased lung volumes.
We therefore hypothesized that in subjects with
abdominal obesity the main determinant of lung function
impairment is the presence of visceral fat. Therefore, it is
important to gain insight in the association between
visceral fat and lung function impairment. Since measure-
ment of waist circumference does not allow us to estimate
the amount of visceral fat, we [21,22] used Magneticthe direct measurement of visceral and subcutaneous fat
distribution.
We selected a male study group with the metabolic syn-
drome according to the International Diabetes Federation
[23] but without overt diabetes to minimize confounding by
diabetes or gender (fat distribution and hormonal differ-
ences). The aim of the present study was to examine the
association of visceral fat as measured by MRI and lung
function in non-diabetic men with the metabolic syndrome.
Materials and methods
We conducted a cross-sectional analysis of 98 male subjects
aged between 50 and 70 years with the metabolic syndrome
(defined according to the International Diabetes Federation
criteria but without diabetes). This study was an addendum
to a trial study. The inclusion criteria for the participants
were: a waist circumference >94 cm and at least two other
metabolic syndrome criteria: TG 1.7 mmol/l, HDL-chol:
<1.03 mmol/l, blood pressure 130/85 mmHg. Exclusion
criteria were the presence of type 2 diabetes, overt car-
diovascular disease, use of statins or fibrates, and a BMI
>40 kg/m2. For this study we used the measurements taken
at the end of the trial.
This study was an addendum to a double-blind placebo
controlled randomized trial, testing the hypothesis that
rosiglitazone 8 mg (4 mg bd) would prevent progression of
atherosclerosis more than placebo in visceral obese male
subjects with systemic inflammation. This was defined by
hs-CRP levels higher than 1.8 mg/L and in their control
patients with the metabolic syndrome and a hs-CRP lower
than 1.8 mg/L.
After the placebo-controlled trial was finished 110 pa-
tients were invited a visit the lung department and 98 pa-
tients agreed to a lung function analysis which was
performed after informed consent. The addendum to the
protocol was approved by the local review board (LUMC, 14-
5-2007 Protocol P04.232).
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Clinical assessments
Clinical history, physical examination including blood
pressure measurements, and anthropometry, and labora-
tory assessments were performed at the clinical research
unit at the end of the trial. Blood pressure was recorded in
supine position after 15 min rest. Blood pressure was
defined as the mean value of 3 measurements taken with
intervals of at least 2 min. Body weight and body length
were measured. Waist circumference was measured in a
horizontal plane between the lowest costal margin and the
upper pelvic rim. Hip circumference is measured at the
level of the major trochanters. Circumferences were
recorded in centimeters.
Laboratory measurements included fasting glucose, tri-
glyceride, total- and HDL-cholesterol and hs-CRP levels,
measured at the department of clinical chemistry.
MRI measurements
Subjects were positioned in the magnet in a supine position.
The body coil was used for obtaining the images. A sagittal
single shot gradient echo sequence survey scan was used for
the imaging of the vertebral column in the lumbar region.
Subsequently, a second single shot gradient echo sequence in
the transversal plane was used for obtaining three contig-
uous slices of 10 mm without angulations with the following
parameters: echo time 3.7 ms (TE), repetition time7.5 ms
(TR), pulse angle 45. Two signal averages were performed.
The slices were centered at the intervertebral disk level
between the fourth and fifth lumbar vertebra. The images
were obtained with three breath holds of 6 s. The field of
view was 500 mm. A voxel size of 1 mm  1.3 mm  10 mm
was obtained. The measurements were taken at the end of
the trial and images were assessed using the MASS software
package allowing a semi-automated detection of subcu-
taneous and visceral adipose tissue area.
Flow volume curve and reversibility
Flow-volume curves were recorded, after the placebo
controlled Rosiglitazone trial ended, by pneumotachograph
to obtain the vital capacity (VC), expiratory rest volume
(ERV), forced expiratory volume in 1 s (FEV1) and the
forced vital capacity (FVC). To test whether the obstruc-
tion is reversible to bronchodilators, FEV1 and FVC (abso-
lute values and percentage of predicted values) were
measured before and 15 min after four single inhalations of
100 mcg albuterol administered through a large volume
spacer.
Exhaled NO
Exhaled NO measurements were measured with a chem-
iluminescence analyzer (Aerocrine AB, Niox, Solna, Swe-
den) according to a standardized procedure. After inhaling
NO-free air, the subjects performed a slow expiratory vital
capacity maneuver with a constant expiratory flow of
50 ml/s against a resistance of 10 cm H2O using online visual
monitoring. Exhaled NO concentrations were determined at
a 3 s-plateau and expressed as parts per billion (ppb). If the
chemiluminescence analyzer was not available exhaled ni-
tric oxide was measured using a portable analyzer, the NIOXMINO (Aerocrine AB, Solna, Sweden) following the manu-
facturer’s instructions.
Subjects performed a 10 s slow steady exhalation, which
was assisted by visual and audio biofeedback systems
located on the device. The two methods used give com-
parable results [24]. Three successive recordings at 1-
min intervals were made and the mean exhaled NO was
used. Exhaled NO was considered to be elevated above
25 ppb [25].
Statistical analyses
The data are presented as median and 25th and 75th
percentile, or percentage. Triglycerides, exhaled nitric
oxide and hs-CRP values were log transformed for statistical
analysis due to their non-normal distribution. Linear
regression was used to assess the association between lung
function and the different features of fat and metabolic
syndrome. Adjustments were made for age, pack years, hs-
CRP, rosiglitazone, glucose, cholesterol and blood pressure.
A restriction analysis that excluded participants with
decreased lung function was performed. Results were
considered significant at p < 0.05 and the data were
analyzed using the Statistical Package of Social Science
(SPSS) version 20.0.Results
All analyses were conducted on 98 participants. We
included 81 men with metabolic syndrome and CRP levels
higher than 1.8 mg/L (of which 40 participants used Rosi-
glitazone) and 17 control patients with the metabolic syn-
drome and hs-CRP levels lower than 1.8 mg/L.
The characteristics of the study population after the
trial are presented in Table 1. Most patients were found to
have no significant airway obstruction and no or little
airway inflammation (as assessed by exhaled nitric oxide
measurement), data presented in Table 2.
In the linear regression no association was found be-
tween any of the features of the metabolic syndrome and
FEV1, FVC and exhaled nitric oxide. Rosiglitazone use was
also not correlated with any of these lung function mea-
surements. However, whereas BMI and features of the
metabolic syndrome, including waist circumference, were
not associated with FEV1 and FVC there was a significant
association between waist visceral fat, and FEV1 (beta
0.023; 95% CI 0.041, 0.006); this means that an addi-
tional 200 cm2 of visceral fat (the IQR within this study) is
associated with a 4.6% decrease in FEV1 predicted. There
was also an association with FVC (beta 0.024; 95% CI
0.040, 0.008), but not between subcutaneous fat and
FEV1 and FVC (Figs. 1 and 2).
After adjustment for waist subcutaneous fat, age,
height, waist circumference, pack years, rosiglitazone use,
hs-CRP, glucose, cholesterol, triglyceride and blood pres-
sure the association between visceral fat and FEV1 (beta
0.055; 95% CI 0.085, 0.025) and FVC (beta 0.040; 95%
CI 0.067, 0.014) remained.
There was also a significant association between waist
visceral fat and ERV (beta 0.108; 95% CI 0.157, 0.058)
and waist subcutaneous fat and ERV (beta 0.070; 95% CI
0.108, 0.032). After adjustment for age, pack years,
Table 1 Baseline characteristics.








Age (years) 62 (57e64) 62 (57e64) 62 (59e65) 61 (57e64)
PY (years) 15 (0.3e29) 16 (2e30) 15 (1.5e27) 7 (0e21)
BMI (kg/m2) 28.9 (26.4e30.7) 28.1 (26.5e30.7) 28.1 (26.1e30.8) 27.8 (26.3e30.8)
BP systolic (mmHg) 139 (129e152) 137 (127e144) 134 (125e149) 149 (137e164)
BP diastolic (mmHg) 82 (74e88) 79 (63e68) 80 (74e84) 92 (84e97)
Waist circumference (cm) 102 (96e109) 100 (94e112) 100 (96e108) 104 (101e109)
Glucose (mmol/l) 5.0 (4.6e5.3) 4.9 (4.4e5.3) 4.9 (4.6e5.4) 5.2 (4.7e5.4)
Triglyceride (mmol/l) 1.7 (0.8e2.1) 1.2 (0.8e1.8) 1.2 (0.8e2.1) 2.6 (1.5e3.5)
HDL-Cholesterol (mmol/l) 1.4 (1.1e1.6) 1.5 (1.2e1.7) 1.3 (1.1e1.5) 1.1 (1.0e1.2)
hs-CRP (mg/l) 1.4 (0.7e2.6) 1 (0.6e2.5) 2.2 (1.4e3.1) 0.9 (0.6e1.3)
Waist visceral fat (cm2) 343 (288e486) 338 (272e575) 328 (287e436) 386 (300e502)
Waist subcutaneous fat (cm2) 700 (610e885) 736 (623e911) 739 (596e914) 649 (520e807)
Values are median (25th, 75th percentiles). PY is pack years, BMI is body mass index and BP is blood pressure.
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pressure the association between visceral fat and ERV (beta
0.116; 95% CI 0.181, 0.052) and subcutaneous fat and
ERV (beta 0.059; 95% CI 0.105, 0.014) remained.
To assess whether the association between visceral fat
and FEV1 and FVC is explained by ERV we explored the as-
sociation. ERV was associated with FEV1 (beta 1.1; 95% CI
0.6, 1.6) and FVC (beta 1.4; 95% CI 0.8, 1.9). Eight partic-
ipants had a FEV1 below 80% excluding these participants
did not alter these results.
Waist subcutaneous fat had a stronger association (beta
19.6; 95% CI 16.1, 23.2) with waist circumference than
visceral fat (beta 13.6; 95% CI 11.1, 16.2). Whereas hs-CRP
showed a weak negative association with FEV1, after
correction for waist visceral fat this was no longer signifi-
cant. No association was found between log hs-CRP and FVC
and exhaled nitric oxide.Discussion
The results of this study show that in men at an early stage




FEV1 post pred (%) 105 (96e118) 104 (92e
FVC post pred (%) 108 (95e118) 106 (94e
FEV1/FVC (%) 79 (73e84) 78 (73e
VC (%) 109 (96e118) 108 (96e
ERV (%) 88 (61e124) 85 (56e
NO (ppb) 16 (11e24) 15 (9e
Values are means, median (25th, 75th percentiles). FEV1 is forced exp
VC is vital capacity post predicted, ERV is expiratory reserve volumenormal lung function there is a significant linear inverse
relation between visceral, but not subcutaneous fat, and
FEV1 and FVC. In contrast, there was no correlation be-
tween subcutaneous fat (or other fat measurements) and
FEV1 and FVC. Exhaled nitric oxide was not correlated with
the metabolic syndrome and the fat measurements. This
indicates that in non-diabetic subjects with the metabolic
syndrome, visceral fat appears to be a more sensitive
parameter to assess the association between obesity and
lung function impairment than subcutaneous fat or waist
circumference.
Our results are in line with those published by Leone
et al. [16] and by Lam et al. [15], who reported a positive
relationship between lung function impairment and meta-
bolic syndrome, which was explained mainly by abdominal
obesity and was independent of the body mass index. We
did not find such an association with abdominal obesity,
which might be because our study focused on subjects with
a high waist circumference and the other studies were
population-based studies. We did find a significant associ-
ation with visceral fat, which may be explained by the fact
that waist circumference is predominantly an index of









114) 106 (97e127) 109 (91e124)
113) 111 (98e121) 109 (93e117)
83) 82 (73e85) 79 (73e83)
115) 109 (100e121) 110 (97e123)
115) 97 (68e128) 94 (62e129)
28) 17 (11e22) 15 (12e27)
iratory volume in 1 s, FVC is forced vital capacity post predicted,
and NO is exhaled Nitric oxide.
Figure 1 The correlation between visceral fat (cm2), subcutaneous fat (cm2), waist circumference (cm), BMI (kg/m2) and
FEV1 (%). The Pearson correlation: visceral fat (cm
2) and FEV1 (%) r Z 0.180 p Z 0.038, subcutaneous fat (cm2) and FEV1 (%)
rZ 0.009 pZ 0.463, waist circumference (cm) and FEV1 (%) rZ 0.037 pZ 0.357, BMI (kg/m
2) and FEV1 (%) rZ 0.027 pZ 0.401.
Figure 2 The correlation between visceral fat (cm2), subcutaneous fat (cm2), waist circumference (cm), BMI (kg/m2) and FVC
(%). The Pearson correlation between: visceral fat (cm2) and FVC (%) r Z 0.200 p Z 0.025, subcutaneous fat (cm2) and FVC (%)
rZ 0.069 pZ 0.251, waist circumference (cm) and FVC (%) rZ 0.038 pZ 0.355, BMI (kg/m2) and FVC (%) rZ 0.031 pZ 0.387.
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356 W. Thijs et al.Indeed, in our study the relation between subcutaneous fat
and waist circumference was stronger than the association
between visceral fat and waist circumference.
How do we interpret the present findings? Obesity may
limit lung expansion due to the mechanical pressure of the
abdomen and cause restriction. Although we can not
formally exclude that the association between visceral fat
and lung function impairment is also explained by me-
chanical factors, it is important to note that in this small
selected group no relation with waist circumference or BMI
was found. Therefore, visceral fat appears to be a more
selective marker in the relationship of abdominal obesity
and lung function impairment.
This higher selectivity may be explained by the
observation that adipocytes present in visceral fat are a
more important source of pro-inflammatory mediators
than adipocytes present in subcutaneous fat [19]. In some
studies, visceral fat was found to be correlated with
levels of CRP, which is mainly liver derived [26,27]. Al-
though this indicates that increased inflammation result-
ing from an increase in visceral fat may contribute to
lung function impairment, it needs to be noted that we
did not find a correlation between markers of inflamma-
tion (exhaled NO and hs-CRP) and visceral fat. However,
we did not measure other (adipocyte-derived) pro-
inflammatory mediators such as leptin that may be
related to visceral fact.
Our study was subject to some limitations. Firstly, the
majority of subjects was recruited after finishing a ran-
domized controlled trial with Rosiglitazone, and therefore
half of the subjects received Rosiglitazone 8 mg during a
year previous to our lung function measurements. However,
it is unlikely that this treatment affected the outcome of
the present study, since similar results were found after
statistical adjustment for use of Rosiglitazone. Secondly,
whereas the patients that participated in the Rosaglitazone
trial all were characterized by a hs-CRP >1.8 mg/L, an
additional group was studied with metabolic syndrome but a
hs-CRP <1.8 mg/L. Furthermore, we used the measure-
ments taken after the trial which were closer to each other.
This resulted in a study group with heterogeneous CRP
levels. This is unlikely to have influenced our results
because these were identical after adjustment for hs-CRP.
Finally, due to the cross-sectional design of our study no
follow-up lung-function data or parameters of the meta-
bolic syndrome were available.
The observed association between visceral fat and lung
function measurement impairment was found despite the
fact that the study subjects all had increased waist
circumference (and therefore likely increased visceral fat)
and a lung function that was within a normal range. Further
studies are needed to clarify the link between visceral fat,
inflammation and lung function impairment and should
include study groups with a larger range of visceral fat and
lung function. We hypothesize that in such groups the
observed association may even be stronger. In addition,
measurements of a range of adipocyte-derived pro-inflam-
matory mediators such as leptin would contribute to our
understanding.
In conclusion, we have shown an association between
lung function impairment and visceral fat in non-diabetic
men with the metabolic syndrome and a normal range oflung function. The observation that such an association
with lung function impairment was not found with other
parameters of obesity indicates that visceral fat is a more
sensitive parameter to assess the association between
abdominal obesity (a component of the metabolic syn-
drome) and lung function impairment.Conflict of interest
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